St. Baldrick’s is a volunteer-driven charity committed to funding the most promising research to find cures for childhood cancers and give survivors long and healthy lives.
Grants are offered in seven funding categories for childhood cancer research:
- Post-Doctoral Fellowship for Childhood Cancer Research (Fellow)
- St. Baldrick’s Scholar (Career Development Award)
- St. Baldrick’s International Scholar (Career Development Award)
- Childhood Cancer Research Grant
- Consortium Research Grant
- Supportive Care Research Grant
- St. Baldrick’s Summer Fellows(Institutions with a pediatric oncology research summer fellowship program should review the updated 2015 Grant Guidelines for requirements and contact Grants@StBaldricks.org for more information on how to apply by the January 30 deadline.)
For more information contact:
(626) 792-8247, ext. 236
1333 South Mayflower Ave
Monrovia, CA 91016
McKnight Endowment Fund for Neurosciences
2015 McKnight Scholar Awards
These awards were established to encourage emerging neuroscientists to focus on disorders of learning and memory. Applicants for the McKnight Scholar Awards must demonstrate interest in solving important problems in relevant areas of neuroscience, including the translation of basic research to clinical neuroscience.
Deadline: January 7, 2015
In September 2014, BU’s Government Relations office hosted Michael Ledford, Vice President, Lewis-Burke Associates LLC, who delivered a presentation on the Department of Defense Health Research Programs.
The presentation covered current cross-cutting trends and priorities, specific DOD programs which engage most directly with university researchers, and techniques for navigating the DOD health landscape. The presentation reviewed more than 15 targets for research, including the Army Medical Research and Materiel Command, the Congressionally Directed Medical Research Program, the Defense Medical Research and Development Program, the Defense Advanced Research Projects Agency, and the Defense Threat Reduction Agency.
If you missed the live presentation, the slides and video from the event are now available for your viewing. Please note, you will need your Kerberos credentials to view both files.
The Dan David Prize, a joint international enterprise endowed by the Dan David Foundation and headquartered at Tel Aviv University, aims to foster universal values of excellence, creativity, justice, democracy, and progress and to promote the scientific, technological, and humanistic achievements that advance and improve our world. The Prize covers three time dimensions – Past, Present, and Future – that represent realms of human achievement. The Past refers to fields that expand knowledge of former times. The Present recognizes achievements that shape and enrich society today. The Future focuses on breakthroughs that hold great promise for improvement of our world.
The themes for the 2015 competition cycle are:
- Past – Retrieving the Past: Historians and their Sources
- Present – The Information Revolution
- Future – Bioinformatics
One million dollars per each field.
- Nominees may be individuals or organizations. Specific and unique projects may be included if the head of the project is a nominee.
- The individual or institution being nominated must have made a unique, profound contribution to humanity, on a global scale, in one of the selected fields.
- The work for which a nominee’s recognition is sought may represent a singular achievement, a series of achievements, or a life’s work.
- An individual or organization can only receive the Prize once for the same achievement and/or contribution.
- Self-nominations will not be accepted.
Sponsor Deadline: Sunday, November 30, 2014
Free to Breathe has a new funding opportunity solely focused on research to prevent or stop lung cancer metastasis. The foundation will only consider Letters of Intent proposing research to prevent or stop lung cancer metastasis including a clear vision and plan for clinical translation within three years.
- Letter of intent deadline: November 7th, 2014
- Invitation for submission of full application: January 7th, 2015
- Full application deadline: March 9th, 2015
- Applicant notification: May 15th, 2015
- Anticipated funding start date: June 1st, 2015
Visit the Free to Breathe website more information.
- Internal Deadline: September 8, 2014
- NSF Preliminary Proposal Deadline: October 21, 2014
- Final Proposals (by invitation) Deadline: May 15, 2015
Partnerships for International Research and Education (PIRE) is an NSF-wide program that supports international activities across all NSF supported disciplines. The primary goal of PIRE is to support high quality projects in which advances in research and education could not occur without international collaboration. PIRE seeks to catalyze a higher level of international engagement in the U.S. science and engineering community. PIRE promotes excellence in science and engineering through international collaboration and facilitates development of a diverse, globally-engaged, U.S. science and engineering workforce.
This PIRE competition will be open to all areas of science and engineering research which are supported by the NSF.
There are no restrictions or limits on who can serve as a PI as long as they have or request PI status through Boston University. Proposals may be submitted by U.S. academic institutions with Ph.D.-granting programs that have awarded doctoral degrees in the 2012 or 2013 academic years in any area of research supported by NSF. Note that universities are limited to one proposal as the lead institution. There is no limit on the number of proposals in which an institution can participate as a partner. Full proposals will be accepted by invitation only. For the purposes of this opportunity, Boston University and Boston University Medical Campus will be considered separate institutions allowing one preliminary proposal from each.
NSF intends to award a total of $10 million-$15 million for this round of PIRE. Pending the availability of funds, NSF will make average awards of approximately $4 million over five years. Additional funding for international partners on PIRE projects may be available from selected NSF counterpart agencies abroad.
BUMC may submit only one application to the PIRE program. Potential applicants will be reviewed internally to select the final candidate. If you would like to apply, please email the following documents (preferably combined into a single pdf file) to Diana Lehman (email@example.com), Office of Clinical Research by September 8, 2014:
- a one-page project summary describing the concept of the proposed PIRE project, including why the international partnership is critical to the project success and the broader impacts of the project
- Junior faculty (instructors and assistant professors should include a support letter from their research mentors
- your email address and your mentor’s email address
- your biosketch or cv
Reconstructive Transplantation Research Funding Opportunity for Fiscal Year 2014
One notable addition in the recent Fiscal year 2014 (FY14) Defense Appropriations Act is $15 million (M) to the Department of Defense for the Reconstructive Transplantation Research Program (RTR) to support the science and execution of complex limb and face transplants. This program is administered by the US Army Medical Research and Materiel Command, the Clinical and Rehabilitative Medicine Research Program (CRMRP), through the Office of Congressionally Directed Medical Research Programs (CDMRP) and the Tissue Injury and Regenerative Medicine Project Management Office. News release was issued on June 20, 2014.
No actual Request for Applications is open yet. More on this program: http://cdmrp.army.mil/pubs/press/2014/14rtrppreann.shtml
The Consortium to Alleviate PTSD has a Request for Applications (RFA) out for funding affiliated with their award. Detailed descriptions of the CAP funding opportunity, evaluation criteria, and submission requirements can be found in the Request for Applications available electronically for downloading from the CAP website
Over the past 49 years, the PhRMA Foundation has helped thousands of scientists advance their careers and has inspired new generations to enter biopharmaceutical research. The early-career support provided by the PhRMA Foundation has been a catalyst for our scientists to become leaders in their organizations and fields. Our programs help build a larger pool of highly-trained researchers to meet the growing needs of academic institutions, the government and the research-intensive pharmaceutical industry.
The PhRMA Foundation funds scientists at critical points in their research careers to support and reward innovation in disciplines essential to the development of safe and effective medicines. The PhRMA Foundation offers competitive pre and post doctoral fellowships, sabbatical fellowships, and research starter grants to advance science in pharmacology, toxicology, informatics, pharmaceutics, and health outcomes. The Foundation also offers a Comparative Effectiveness Research Center of Excellence Award.
PhRMA Foundation award recipients will continue to play an instrumental role in substantial achievements in medicine for the benefit of public health and ultimately the patient.
The BUMC Transgenic Core, established in 1995 by Dr. Katya Ravid, has played an important role in the activities of many scientists at our institution. As part of the continual evaluation of all cores, a faculty committee was established to advise Provost Antman and me on the future role of transgenic services at BUMC.
The committee members were unanimously in favor of maintaining a Transgenic Core facility at BU and increasing its capabilities to serve a larger user group. While the committee recognized that implementation of this recommendation will require new investment at a time of fiscal uncertainty, they were convinced that a transgenic core providing state-of-the-art services is essential for maintaining and growing the University’s research portfolio.
After careful consideration of her many leadership commitments, Dr. Ravid has chosen to step down as Scientific Director of the core because of conflicting time commitments. We would like to thank Dr. Ravid for her creative work and efforts on behalf of the institution in establishing and directing the core over the past 20 years. Her insights and efforts contributed to the success of many research projects and grants at BU.
Dr. Kenn Albrecht, a developmental geneticist with broad expertise in the creation and analysis of mouse models of human disease and a collaborator of Dr. Ravid and the Transgenic Core on multiple projects, has agreed to become the new Scientific Director. Please join me in thanking Dr. Ravid for her efforts and Dr. Albrecht for continuing the mission of the Transgenic Core Facility.